Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The sale is being conducted by Zhejiang Health Road Technology Group Co., Ltd., a wholly-owned subsidiary of the company [1] - The proceeds from the sale will be used to develop the company's enterprise services and digital marketing services [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became evident, leading to a significant drop in revenue and net profit starting from August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1]
健康之路(02587)附属拟出售福建健宸医药有限公司51%的股权